Grey Wolf Therapeutics Announces Clinical Supply Agreement with Regeneron for Trial Evaluating GRWD5769 in Combination with Libtayo® (cemiplimab)
- Wednesday, November 16, 2022, 7:04
- Finance
- Add a comment
Combination of First-in-Class ERAP1 Inhibitor and Anti-PD-1 Monoclonal Antibody to be Studied in Patients with a Range of Advanced Solid Tumours OXFORD, United Kingdom and MELBOURNE, Australia, Nov. 16, 2022 /PRNewswire/ — Grey Wolf Therapeutics, a biotechnology company focused on…
About the Author
adminasapcorp has written 41828 stories on this site.